BEAM THERAPEUTICS INC.

26,45

08-ноября-24 12:55:31

15 мин. задержка

Акции

+0,35

+1,34%

Сегодняшний диапазон

25,68 - 26,93

ISIN

N/A

Источник

NASDAQ

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

05 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

29 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

06 авг 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Announces Transition of Chief Financial Officer

15 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

26 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

14 июн 2024 03:00:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

30 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

14 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

08 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

07 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

26 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

28 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

27 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

08 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

14 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

08 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

08 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.